OFIX vs. SRDX, ANGO, ARAY, ATRC, ATEC, IRMD, PLSE, OSUR, SKIN, and EMBC
Should you be buying Orthofix Medical stock or one of its competitors? The main competitors of Orthofix Medical include Surmodics (SRDX), AngioDynamics (ANGO), Accuray (ARAY), AtriCure (ATRC), Alphatec (ATEC), Iradimed (IRMD), Pulse Biosciences (PLSE), OraSure Technologies (OSUR), Beauty Health (SKIN), and Embecta (EMBC). These companies are all part of the "surgical & medical instruments" industry.
Orthofix Medical (NASDAQ:OFIX) and Surmodics (NASDAQ:SRDX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.
Surmodics has lower revenue, but higher earnings than Orthofix Medical. Orthofix Medical is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.
89.8% of Orthofix Medical shares are held by institutional investors. Comparatively, 96.6% of Surmodics shares are held by institutional investors. 4.7% of Orthofix Medical shares are held by insiders. Comparatively, 8.9% of Surmodics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Orthofix Medical received 72 more outperform votes than Surmodics when rated by MarketBeat users. However, 67.13% of users gave Surmodics an outperform vote while only 61.78% of users gave Orthofix Medical an outperform vote.
Orthofix Medical has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Surmodics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.
In the previous week, Surmodics had 16 more articles in the media than Orthofix Medical. MarketBeat recorded 18 mentions for Surmodics and 2 mentions for Orthofix Medical. Surmodics' average media sentiment score of 0.53 beat Orthofix Medical's score of -0.32 indicating that Surmodics is being referred to more favorably in the news media.
Orthofix Medical currently has a consensus target price of $15.50, suggesting a potential upside of 13.97%. Surmodics has a consensus target price of $57.00, suggesting a potential upside of 75.44%. Given Surmodics' stronger consensus rating and higher probable upside, analysts clearly believe Surmodics is more favorable than Orthofix Medical.
Surmodics has a net margin of 9.44% compared to Orthofix Medical's net margin of -20.28%. Surmodics' return on equity of 13.30% beat Orthofix Medical's return on equity.
Summary
Surmodics beats Orthofix Medical on 15 of the 18 factors compared between the two stocks.
Get Orthofix Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OFIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OFIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orthofix Medical Competitors List
Related Companies and Tools
